These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8118266)

  • 21. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
    Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
    Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
    PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
    Hofmann R; Lehmer A; Hartung R; Robrecht C; Buresch M; Grothe F
    J Urol; 1996 Mar; 155(3):858-62. PubMed ID: 8583593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
    Hildenbrand R; Dilger I; Hörlin A; Stutte HJ
    Pathol Res Pract; 1995 Jun; 191(5):403-9. PubMed ID: 7479358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
    Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
    Jankun J; Merrick HW; Goldblatt PJ
    J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
    Schmitt M; Mengele K; Napieralski R; Magdolen V; Reuning U; Gkazepis A; Sweep F; Brünner N; Foekens J; Harbeck N
    Expert Rev Mol Diagn; 2010 Nov; 10(8):1051-67. PubMed ID: 21080821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM; Conti L; Vercillo M
    Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers of the uPA system and common prognostic factors in breast cancer.
    Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
    Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
    Whitley BR; Palmieri D; Twerdi CD; Church FC
    Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma].
    Geleţu G; Plămădeală P; Gogălniceanu D; Zeilhofer HF; Popescu E; Moscalu M
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):79-84. PubMed ID: 15688761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irreversible inhibition and peptide mapping of urinary plasminogen activator urokinase.
    Reboud-Ravaux M; Desvages G; Chapeville F
    FEBS Lett; 1982 Apr; 140(1):58-62. PubMed ID: 7044821
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prognostic factors in lymph node negative breast cancer].
    Kleeberg UR
    Strahlenther Onkol; 2002 Jan; 178(1):53-4. PubMed ID: 11977395
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular accumulation of uPA-PAI-1 [correction of UPA-PAI-1] and uPA-PAI-2 [correction of UPA-PAI-2] complexes in early (pT1) breast cancer: a new link in the uPA-UPAr-PAI chain.
    Schneider J; Lucas R; Sánchez J; Tejerina A; Ruibal A
    In Vivo; 2000; 14(4):507-11. PubMed ID: 10945166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment].
    Schneeweiss A; Thomssen Ch; Harbeck N; Bastert G
    MMW Fortschr Med; 2003 Jun; 145(24):34-6, 38. PubMed ID: 12866297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].
    Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE
    Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.